Company Profile: Sienna Cancer Diagnostics Ltd (ASX: SDX), established in 2002, is a medical technology company that is based out of Australia and operating across Australia, the United States, and Europe. The services include biotechnology and pharmaceutical R&D, commercialisation, manufacturing operation, and other allied services for clinical diagnostic laboratories. The company specifically operates through its platform that is based on the technology for detecting biomarker telomerase, which is present in almost all kind of epithelial cancers.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500. Click here for your FREE Report